Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins

por Kalemera, Mphatso D., Capella-Pujol, Joan, Chumbe, Ana, Underwood, Alexander, Bull, Rowena A., Schinkel, Janke, Sliepen, Kwinten, Grove, Joe
Publicado 2020

Understanding the Determinants of BnAb Induction in Acute HCV Infection

por Underwood, Alexander P., Walker, Melanie R., Brasher, Nicholas A., Eltahla, Auda A., Maher, Lisa, Luciani, Fabio, Lloyd, Andrew R., Bull, Rowena A.
Publicado 2018

A Hepatitis C Virus DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice

por Masavuli, Makutiro Ghislain, Wijesundara, Danushka K., Underwood, Alexander, Christiansen, Dale, Earnest-Silveira, Linda, Bull, Rowena, Torresi, Joseph, Gowans, Eric J., Grubor-Bauk, Branka
Publicado 2019

Clearance of hepatitis C virus is associated with early and potent but narrowly-directed, Envelope-specific antibodies

por Walker, Melanie R., Leung, Preston, Eltahla, Auda A., Underwood, Alexander, Abayasingam, Arunasingam, Brasher, Nicholas A., Li, Hui, Wu, Bing-Ru, Maher, Lisa, Luciani, Fabio, Lloyd, Andrew R., Bull, Rowena A.
Publicado 2019

Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19

por Underwood, Alexander P., Sølund, Christina, Fernandez-Antunez, Carlota, Villadsen, Signe Lysemose, Winckelmann, Anni Assing, Bollerup, Signe, Mikkelsen, Lotte S., Sørensen, Anna-Louise, Feng, Shan, Fahnøe, Ulrik, Lassauniere, Ria, Fomsgaard, Anders, Ramirez, Santseharay, Weis, Nina, Bukh, Jens
Publicado 2021

Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication

por Ramirez, Santseharay, Fernandez-Antunez, Carlota, Galli, Andrea, Underwood, Alexander, Pham, Long V., Ryberg, Line A., Feng, Shan, Pedersen, Martin S., Mikkelsen, Lotte S., Belouzard, Sandrine, Dubuisson, Jean, Sølund, Christina, Weis, Nina, Gottwein, Judith M., Fahnøe, Ulrik, Bukh, Jens
Publicado 2021

Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA–mRNA or Vector–mRNA COVID-19 Vaccines

por Sølund, Christina, Underwood, Alexander P., Fernandez-Antunez, Carlota, Bollerup, Signe, Mikkelsen, Lotte S., Villadsen, Signe Lysemose, Fahnøe, Ulrik, Winckelmann, Anni Assing, Feng, Shan, Nørløv Vinten, Caroline A., Dalegaard, Magnus Illum, Vizgirda, Greta, Sørensen, Anna-Louise, Ramirez, Santseharay, Bukh, Jens, Weis, Nina
Publicado 2022

In vitro Characterization of Fitness and Convalescent Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink at Danish Farms

por Lassaunière, Ria, Fonager, Jannik, Rasmussen, Morten, Frische, Anders, Polacek, Charlotta, Rasmussen, Thomas Bruun, Lohse, Louise, Belsham, Graham J., Underwood, Alexander, Winckelmann, Anni Assing, Bollerup, Signe, Bukh, Jens, Weis, Nina, Sækmose, Susanne Gjørup, Aagaard, Bitten, Alfaro-Núñez, Alonzo, Mølbak, Kåre, Bøtner, Anette, Fomsgaard, Anders
Publicado 2021

Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination

por Underwood, Alexander P., Sølund, Christina, Fernandez-Antunez, Carlota, Villadsen, Signe Lysemose, Mikkelsen, Lotte S., Fahnøe, Ulrik, Bollerup, Signe, Winckelmann, Anni Assing, Schneider, Uffe Vest, Binderup, Alekxander, Vizgirda, Greta, Sørensen, Anna-Louise, Vinten, Caroline Nørløv, Dalegaard, Magnus Illum, Ramirez, Santseharay, Weis, Nina, Bukh, Jens
Publicado 2023

Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design

por Keck, Zhen-Yong, Pierce, Brian G., Lau, Patrick, Lu, Janine, Wang, Yong, Underwood, Alexander, Bull, Rowena A., Prentoe, Jannick, Velázquez-Moctezuma, Rodrigo, Walker, Melanie R., Luciani, Fabio, Guest, Johnathan D., Fauvelle, Catherine, Baumert, Thomas F., Bukh, Jens, Lloyd, Andrew R., Foung, Steven K. H.
Publicado 2019

First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2

por Smit, Merel J, Sander, Adam F, Ariaans, Maud B P A, Fougeroux, Cyrielle, Heinzel, Constanze, Fendel, Rolf, Esen, Meral, Kremsner, Peter G, ter Heine, Rob, Wertheim, Heiman F, Idorn, Manja, Paludan, Søren Riis, Underwood, Alexander P, Binderup, Alekxander, Ramirez, Santseharay, Bukh, Jens, Soegaard, Max, Erdogan, Sayit M, Gustavsson, Tobias, Clemmensen, Stine, Theander, Thor G, Salanti, Ali, Hamborg, Mette, de Jongh, Willem A, McCall, Matthew B B, Nielsen, Morten A, Mordmüller, Benjamin G
Publicado 2023